Table 3.
Trial | Resectability | Number of patients | Treatment arms | Status |
---|---|---|---|---|
NEONAX (48) | R | 166 | Gemcitabine/Nab-paclitaxel + Surgery + adjuvant Gemcitabine/Nab-paclitaxel versus Surgery + adjuvant Gemcitabine/Nab-paclitaxel | Recruiting |
NEOPAC (47) | R | 310 | Gemcitabine + Oxaliplatin + Surgery + adjuvant Gemcitabine versus Surgery + adjuvant Gemcitabine | Completed |
NORPACT-1 (49) | R | 90 | FOLFIRINOX + Surgery + adjuvant Gemcitabine/Capecitabine versus Surgery + adjuvant Gemcitabine/Capecitabine | Recruiting |
PANACHE01-PRODIGE48 (50) | R | 168 | mFOLFIRINOX + Surgery + adjuvant chemotherapy versus FOLFOX + Surgery + adjuvant chemotherapy versus Surgery + adjuvant chemotherapy | Recruiting |
ALLIANCE A021806 | R | 352 | mFOLFIRINOX + Surgery versus Surgery + adjuvant mFOLFIRINOX | Recruiting |
PREOPANC-2 (51) | R/BR | 375 | FOLFIRINOX + Surgery versus Gemcitabine + CRT (Gemcitabine + 36 Gy RT) + Surgery + adjuvant Gemcitabine | Completed |
PANDAS-PRODIGE- 44 | BR | 90 | mFOLFIRINOX + CRT (capecitabine + 50.4 Gy RT) + Surgery + adjuvant Gemcitabine (or LV5FU) versus mFOLFIRINOX + Surgery + adjuvant Gemcitabine (or LV5FU) | Recruiting |
R, resectable; BR, borderline resectable; FOLFIRINOX, oxaliplatin, irinotecan, fluorouracil, and leucovorin; mFOLFIRINOX, modified regimen of oxaliplatin, leucovorin, irinotecan, and fluorouracil; chemotherapy, choice at discretion of medical team; LV5FU, infused 5-fluorouracil/folinic acid.